Policy Tracker · Patient Lens · September 21, 2026
A new drug option when weight-loss surgery does not go far enough
One trial targets people whose surgery did not go far enough, while another eyes a completely different addiction use years away.
Key details
- A new GLP-1 drug called Mazdutide is now being trialed for both weight loss and gout.
- Tirzepatide is being tested for methamphetamine addiction, enrolling from October 2026.
- Phase 3 trial will test tirzepatide for people who had surgery and still have obesity.
3 developments affecting GLP-1 access were tracked on Sunday, September 20, 2026, across 1 category. Each entry links to the full record.
## Research and trials
**[Trial tests tirzepatide for failed weight-loss surgery](/fda/clinical-trial-nct07829198)**. A clinical trial will test whether tirzepatide helps people who had weight-loss surgery but didn't lose enough weight.
**[New GLP-1 drug Mazdutide tested for weight loss and gout](/fda/clinical-trial-nct07824895)**. A new GLP-1 drug called Mazdutide is being tested to see if it helps both weight loss and gout in adults with obesity.
**[Tirzepatide tested for methamphetamine addiction in new clinical trial](/fda/clinical-trial-nct07825857)**. A research trial is testing whether tirzepatide can treat methamphetamine addiction, but it won't start enrolling patients until October 2026.
By Amanda Bonello